Results from the Phase 3 NADINA Clinical Trial – Melanoma Institute Australia

Melanoma Institute Australia posted on LinkedIn:

“Heralded as a cancer treatment revolution, the pre-surgery (neoadjuvant) use of combination immunotherapy looks set to become standard treatment for melanoma, and to impact other cancers across the globe.

Ground-breaking results from the Phase 3 NADINA Clinical Trial, an international collaboration co-led by MIA’s Prof Georgina Long and Prof Christian Blank from The Netherlands Cancer Institute.”

Source: Melanoma Institute Australia/LinkedIn